Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Return on Equity (2021 - 2025)

Lyra Therapeutics has reported Return on Equity over the past 5 years, most recently at 3.84% for Q4 2025.

  • Quarterly results put Return on Equity at 3.84% for Q4 2025, up 965.0% from a year ago — trailing twelve months through Dec 2025 was 3.84% (up 965.0% YoY), and the annual figure for FY2025 was 65.95%, down 6410.0%.
  • Return on Equity for Q4 2025 was 3.84% at Lyra Therapeutics, down from 24.15% in the prior quarter.
  • Over the last five years, Return on Equity for LYRA hit a ceiling of 24.15% in Q3 2025 and a floor of 14.19% in Q2 2025.
  • Median Return on Equity over the past 5 years was 0.81% (2023), compared with a mean of 0.96%.
  • Peak annual rise in Return on Equity hit 2794bps in 2025, while the deepest fall reached -1233bps in 2025.
  • Lyra Therapeutics' Return on Equity stood at 1.07% in 2021, then surged by 40bps to 0.64% in 2022, then dropped by -14bps to 0.72% in 2023, then plummeted by -704bps to 5.8% in 2024, then skyrocketed by 166bps to 3.84% in 2025.
  • The last three reported values for Return on Equity were 3.84% (Q4 2025), 24.15% (Q3 2025), and 14.19% (Q2 2025) per Business Quant data.